Company / R&D Expense
Senti Biosciences Holdings, Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$34.4M
FY2025
5-year range
$22.0M / $34.4M
FY2022-FY2025
Trend
+6.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $22M in FY2022 to $34M in FY2025.
Based on SEC 10-K filings.
$34M in FY2025 with a 3-year CAGR of +16.1%.
Improved from $28M to $34M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +16.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Senti Biosciences Holdings, Inc.'s r&d expense has grown for 3 consecutive years.
- 3-year CAGR of +16.1%, indicating consistent growth.
- In FY2025, r&d expense increased 6.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.4M | +6.9% |
| FY2024 | $32.1M | +14.2% |
| FY2023 | $28.1M | +28.2% |
| FY2022 | $22.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026